<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02046486</url>
  </required_header>
  <id_info>
    <org_study_id>LIQUID study</org_study_id>
    <nct_id>NCT02046486</nct_id>
  </id_info>
  <brief_title>OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study (the LIQUID Study)</brief_title>
  <acronym>LIQUID</acronym>
  <official_title>OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective, randomized, single-blind, investigator initiated,&#xD;
      pharmacokinetic/pharmacodynamic study of parallel design.Patients with ST elevation&#xD;
      myocardial infarction (symptom onset&lt;12 hours), undergoing primary percutaneous coronary&#xD;
      intervention, who are P2Y12 inhibitor naïve, will be randomized after informed consent,&#xD;
      immediately after diagnostic coronary angiography, in a 1:1 ratio to either:&#xD;
&#xD;
        -  Ticagrelor 180mg loading dose, in the form of 2 whole tablets administered per os in the&#xD;
           supine position (standard administration)&#xD;
&#xD;
        -  Ticagrelor 180mg loading dose, in the form of 2 tablets crushed and dispersed in&#xD;
           purified water and administered per os with 1-minute-stay in a 60-70 degrees&#xD;
           semi-upright sitting position Platelet reactivity assessment will be performed at&#xD;
           randomization (Hour 0) and at 0.5, 1, 2, 4 and 6 hours after randomization, using the&#xD;
           VerifyNow assay, in platelet reactivity units (PRU). The cutoff &gt;208 PRU will be used&#xD;
           for definition of high platelet reactivity (HPR). All platelet reactivity assessments&#xD;
           will be performed by a physician blind to the actual treatment given. Additional blood&#xD;
           samples will be collected at the same time points for pharmacokinetic analysis. These&#xD;
           samples will be collected in vacuum tubes with lithium heparin and will be kept in ice&#xD;
           until centrifugation (3000 rpm at 4°C for 10 min, within 30 min of sampling). The&#xD;
           resultant plasma will be transferred into a plain polypropylene tube (screw cap) and&#xD;
           stored at or below -20°C until analysed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preparation of Ticagrelor liquid formulation:&#xD;
&#xD;
      Crushed and dispersed Ticagrelor 180mg for oral administration will be prepared as follows:&#xD;
      two ticagrelor 90mg tablets are placed in a mortar and crushed for 60 s using a pestle. 20 mL&#xD;
      of purified water will be added in the mortar and stirred for 60s. The liquid is transferred&#xD;
      to a dosing cup and another 15 mL of purified water is added to the mortar and stirred,&#xD;
      ensuring that all powder has been dispersed and none remained on the mortar and pestle. Again&#xD;
      the liquid is transferred to the dosing cup. The same procedure is repeated with 15 ml of&#xD;
      purified water.The total contents are stirred for another 30 s to ensure that all remaining&#xD;
      tablet particles are dispersed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ticagrelor's Cmax over 1 hour post ticagrelor administration</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the ticagrelor plasma concentration versus time curve (AUC0-1) over 1 hour post ticagrelor administration</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity at 1 hour post randomization</measure>
    <time_frame>1 hour</time_frame>
    <description>Platelet reactivity assessment with the VerifyNow assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPR rate at 1 hour post randomization</measure>
    <time_frame>1 hour</time_frame>
    <description>HPR rate at 1 hour post randomization between the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity at 2 hours post randomization</measure>
    <time_frame>2 hours</time_frame>
    <description>Platelet reactivity assessment with the VerifyNow assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPR rate at 2 hours post randomization</measure>
    <time_frame>2 hours</time_frame>
    <description>HPR rate at 2 hours post randomization between the 2 treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AR-C124910XX Cmax over 1 hour post ticagrelor administration</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AR-C124910XX Cmax over 6 hours post ticagrelor administration</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ticagrelor Cmax over 6 hours post ticagrelor administration</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the AR-C124910XX plasma concentration versus time curve (AUC0-1) over 1 hour post ticagrelor administration</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the AR-C124910XX plasma concentration versus time curve (AUC0-6) over 6 hours post ticagrelor administration</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Ticagrelor plasma concentration versus time curve (AUC0-6) over 6 hours post ticagrelor administration</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for the maximum plasma concentration (Tmax) of Ticagrelor over 6 hours post Ticagrelor administration</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for the maximum plasma concentration (Tmax) of AR-C124910XX over 6 hours post Ticagrelor administration</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor 180mg whole tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor 180mg loading dose, in the form of 2 whole tablets administered per os in the supine position (standard administration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor 180mg crushed and dispersed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 180mg in the form of 2 tablets crushed and dispersed in purified water administered per os with 1-minute-stay in a 60-70 degrees semi-upright sitting position</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 180mg whole tablets</intervention_name>
    <arm_group_label>Ticagrelor 180mg whole tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 180mg crushed and dispersed</intervention_name>
    <arm_group_label>Ticagrelor 180mg crushed and dispersed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years old&#xD;
&#xD;
          2. Patients with STEMI (onset of pain&lt;12 hours) with indication for primary PCI&#xD;
&#xD;
          3. Informed consent obtained in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnancy/Breastfeeding&#xD;
&#xD;
          -  Severe nausea or vomiting&#xD;
&#xD;
          -  Treatment with a P2Y12 inhibitor within the previous 1 month&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous&#xD;
             antiarrhythmic agents&#xD;
&#xD;
          -  Killip class ≥3&#xD;
&#xD;
          -  Known hypersensitivity to ticagrelor&#xD;
&#xD;
          -  History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal&#xD;
             bleeding within the previous 3 months.&#xD;
&#xD;
          -  Other bleeding diathesis, or considered by investigator to be at high risk for&#xD;
             bleeding&#xD;
&#xD;
          -  Thombocytopenia (&lt;100.000 / μL) at randomization&#xD;
&#xD;
          -  Anaemia (Hct &lt;30%) at randomization&#xD;
&#xD;
          -  Polycytaemia (Hct &gt; 52%) at randomization&#xD;
&#xD;
          -  Periprocedural IIb/IIIa inhibitor administration&#xD;
&#xD;
          -  Thrombolysis administration&#xD;
&#xD;
          -  Recent (&lt; 6 weeks) major surgery or trauma, including GABG.&#xD;
&#xD;
          -  Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole,&#xD;
             itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir,&#xD;
             saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A&#xD;
             substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A&#xD;
             inducers (rifampin /rifampicin, phenytoin, carbamazepine).&#xD;
&#xD;
          -  Patients considered by the investigator to be at increased risk of bradycardiac&#xD;
             events.&#xD;
&#xD;
          -  Dialysis required.&#xD;
&#xD;
          -  Severe uncontrolled chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Known severe hepatic impairement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Patras University Hospital Department of Cardiology</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>ticagrelor</keyword>
  <keyword>ST elevation myocardial infarction</keyword>
  <keyword>liquid formulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

